Context Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
CNTX$0.20+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $22,701,335 | $17,782,731 |
| General and administrative | 7,222,565 | 7,289,885 |
| Loss from operations | (29,923,900) | (25,072,616) |
| Interest income | 3,200,224 | 1,163,975 |
| Other expense | (1,428) | (55,570) |
| Net loss | $(26,725,104) | $(23,964,211) |
| Net loss per common share, basic and diluted | $(0.46) | $(1.50) |
| Weighted average shares outstanding, basic and diluted | 58,416,141 | 15,966,053 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.